Literature DB >> 22398864

[Spontaneous bacterial peritonitis].

S A Schmid1, R Wiest, B Salzberger, F Klebl.   

Abstract

Spontaneous bacterial peritonitis (SBP) is the most frequent infection in patients with cirrhosis during hospitalization and is associated with high acute and long-term mortality. Diagnosis is made by paracentesis with determination of neutrophil count in ascitic fluid. Empirical antibiotic therapy must be initiated immediately. The choice of drug is dependent on prior therapies. Liver transplantation has to be considered in the absence of contra-indications. Prophylaxis of SBP is indicated in patients with ascites and gastrointestinal hemorrhage, and in patients after SBP. Primary prophylaxis should be considered in high-risk patients with cirrhosis and ascites. The development of resistance to antibiotic drugs is a relevant side-effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22398864     DOI: 10.1007/s00063-012-0084-3

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  28 in total

Review 1.  Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club.

Authors:  A Rimola; G García-Tsao; M Navasa; L J Piddock; R Planas; B Bernard; J M Inadomi
Journal:  J Hepatol       Date:  2000-01       Impact factor: 25.083

Review 2.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

3.  [German S 3-guideline "ascites, spontaneous bacterial peritonitis, hepatorenal syndrome"].

Authors:  A L Gerbes; V Gülberg; T Sauerbruch; R Wiest; B Appenrodt; M J Bahr; M M Dollinger; M Rössle; M Schepke
Journal:  Z Gastroenterol       Date:  2011-06-01       Impact factor: 2.000

4.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

Authors:  P Sort; M Navasa; V Arroyo; X Aldeguer; R Planas; L Ruiz-del-Arbol; L Castells; V Vargas; G Soriano; M Guevara; P Ginès; J Rodés
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

5.  Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.

Authors:  Javier Fernández; Miquel Navasa; Juliá Gómez; Jordi Colmenero; Jordi Vila; Vicente Arroyo; Juan Rodés
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

6.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

7.  A prospective study of bacterial infections in patients with cirrhosis.

Authors:  W R Caly; E Strauss
Journal:  J Hepatol       Date:  1993-07       Impact factor: 25.083

8.  Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.

Authors:  Jasmohan S Bajaj; Yelena Zadvornova; Douglas M Heuman; Muhammad Hafeezullah; Raymond G Hoffmann; Arun J Sanyal; Kia Saeian
Journal:  Am J Gastroenterol       Date:  2009-03-31       Impact factor: 10.864

9.  Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis.

Authors:  A Umgelter; W Reindl; M Miedaner; R M Schmid; W Huber
Journal:  Infection       Date:  2009-01-23       Impact factor: 3.553

10.  Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study.

Authors:  Kyoung-Ho Song; Jae Hyun Jeon; Wan Beom Park; Sang-Won Park; Hong Bin Kim; Myoung-don Oh; Hyo-Suk Lee; Nam Joong Kim; Kang Won Choe
Journal:  BMC Infect Dis       Date:  2009-04-12       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.